Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease
The FDA has approved Crexont (Amneal), an extended-release capsule formulation of carbidopa/levodopa, for treatment of Parkinson's disease (PD), postencephalitic parkinsonism, and parkinsonism associated with carbon monoxide or manganese intoxication. Crexont contains a combination of immediate-release carbidopa/levodopa granules and extended-release levodopa pellets. An extended-release carbidopa/levodopa oral capsule (Rytary) has been available from the same manufacturer for years; the patent for Rytary expires in 2025.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2024-12-23
- DOI
- https://doi.org/10.58347/tml.2024.1718e
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00